Tezacaftor: all 44 studies that test it

Page 1 of 1. Open to participants first (4), then studies with results posted, then the rest; newest registration first within each.

• Pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor in Cystic FibrosisRecruitingNCT07809867Phase 4
• Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy ParticipantsRecruitingNCT07437105Phase 1
• Evaluation of VX-581 in Healthy Participants and in Participants With Cystic FibrosisRecruitingNCT07283770Phase 1
• Ensuring Access to Optimal Therapy in CF: The ENACT StudyRecruitingNCT07148739Phase 4
• Evaluation of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis (CF) Participants 12 to Less Than 24 Months of AgeCompletedNCT05882357Phase 3Results posted
• Evaluation of Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis Subjects Without an F508del MutationCompletedNCT05274269Phase 3Results posted
• A Study Evaluating the Safety of Elexacaftor/Tezacaftor/Ivacaftor in Participants With Cystic Fibrosis (CF)CompletedNCT05111145Phase 3Results posted
• A Study to Evaluate ELX/TEZ/IVA on Cough and Physical Activity in Participants With Cystic Fibrosis (CF)CompletedNCT04969224Phase 3Results posted
• A Study to Assess the Effect of ELX/TEZ/IVA on Glucose Tolerance in Participants With Cystic Fibrosis (CF)CompletedNCT04599465Phase 3Results posted
• A Study Evaluating the Long-term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis (CF) Particpants 6 Years and Older and F/MF GenotypesCompletedNCT04545515Phase 3Results posted
• Evaluation of ELX/TEZ/IVA in Cystic Fibrosis (CF) Subjects 2 Through 5 YearsCompletedNCT04537793Phase 3Results posted
• A Study Evaluating the Long-Term Safety of Elexacaftor Combination TherapyCompletedNCT04362761Phase 3Results posted
• A Study Evaluating Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis and F/MF GenotypesCompletedNCT04353817Phase 3Results posted
• Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA TC Combination Therapy in Participants With Cystic Fibrosis Who Are 6 Years of Age and OlderCompletedNCT04183790Phase 3Results posted
• A Study Evaluating the Efficacy and Safety of VX-445/Tezacaftor/Ivacaftor in Cystic Fibrosis Subjects, Homozygous for F508delCompletedNCT04105972Phase 3Results posted
• Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination TherapyCompletedNCT04058366Phase 3Results posted
• A Phase 3 Study of VX-445 Combination Therapy in Cystic Fibrosis (CF) Subjects Heterozygous for F508del and a Gating or Residual Function Mutation (F/G and F/RF Genotypes)CompletedNCT04058353Phase 3Results posted
• A Study Evaluating the Long-term Safety of VX-445 Combination TherapyCompletedNCT04043806Phase 3Results posted
• Study of VX-121 in Healthy Subjects and in Subjects With Cystic FibrosisCompletedNCT03768089Phase 1/2Results posted
• Evaluation of VX 445/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of AgeCompletedNCT03691779Phase 3Results posted
• A Study to Evaluate Efficacy and Safety of TEZ/IVA in Subjects Aged 6 Through 11 Years With Cystic FibrosisCompletedNCT03559062Phase 3Results posted
• A Study to Evaluate the Safety and Efficacy of Long-term Treatment With TEZ/IVA in CF Participants With an F508del CFTR MutationCompletedNCT03537651Phase 3Results posted
• A Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination TherapyCompletedNCT03525574Phase 3Results posted
• A Study of VX-445 in Healthy Subjects and Subjects With Cystic FibrosisCompletedNCT03227471Phase 1/2Results posted
• A Study Evaluating the Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic FibrosisCompletedNCT03224351Phase 2Results posted
• A Study to Evaluate Safety, Efficacy, and Tolerability of TEZ/IVA in Orkambi® (Lumacaftor/Ivacaftor) -Experienced Subjects With Cystic Fibrosis (CF)CompletedNCT03150719Phase 3Results posted
• A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of VX-661/Ivacaftor in Pediatric Subjects With Cystic Fibrosis (CF)CompletedNCT02953314Phase 3Results posted
• A Study Evaluating the Safety of VX-152 Combination Therapy in Adults With Cystic FibrosisCompletedNCT02951195Phase 2Results posted
• A Study Evaluating the Safety and Efficacy of VX-440 Combination Therapy in Subjects With Cystic FibrosisCompletedNCT02951182Phase 2Results posted
• A Study to Evaluate the Effect of VX-661 in Combination With Ivacaftor on Chest Imaging Endpoints in Subjects With Cystic Fibrosis, Homozygous for the F508del CFTR MutationCompletedNCT02730208Phase 2Results posted
• A Study to Evaluate the Safety and Efficacy of Long Term Treatment With VX-661 in Combination With Ivacaftor in Participants With Cystic Fibrosis Who Have an F508del-CFTR MutationCompletedNCT02565914Phase 3Results posted
• A Phase 2 Study to Evaluate Effects of VX-661/Ivacaftor on Lung and Extrapulmonary Systems in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR MutationCompletedNCT02508207Phase 2Results posted
• A Phase 3 Study of Tezacaftor (VX-661) in Combination With Ivacaftor (VX-770) in Subjects Aged 12 Years and Older With Cystic Fibrosis (CF), Who Have One F508del-CFTR Mutation and a Second Mutation That Has Been Demonstrated to be Clinically Responsive to IvacaftorCompletedNCT02412111Phase 3Results posted
• A Phase 3 Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-cystic Fibrosis Transmembrane Conductance Regulator (CFTR) MutationCompletedNCT02392234Phase 3Results posted
• Study to Evaluate Safety and Efficacy of VX-661 in Combination With Ivacaftor in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation With an Open-Label ExpansionCompletedNCT02070744Phase 2Results posted
• Study of VX-661 Alone and in Combination With Ivacaftor in Subjects Homozygous or Heterozygous to the F508del-Cystic Fibrosis Transmembrane Conductance Regulator(CFTR) MutationCompletedNCT01531673Phase 2Results posted
• Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and OlderActive, not recruitingNCT06460506Phase 3
• Evaluation of VX-828 in Healthy Participants and in Participants With Cystic FibrosisCompletedNCT06154447Phase 1
• Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508delActive, not recruitingNCT05331183Phase 3
• Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis (CF) Participants 2 Years and OlderCompletedNCT05153317Phase 3
• Real World Clinical Outcomes With Novel Modulator Therapy Combinations in People With CF (RECOVER)Active, not recruitingNCT04602468Phase 4
• Gut Imaging for Function & Transit in Cystic Fibrosis Study 2CompletedNCT04006873Phase 2
• A Study Evaluating Safety and Pharmacokinetics of VX-440 in Combination With Tezacaftor/Ivacaftor in Healthy Adult SubjectsCompletedNCT03486236Phase 1
• An Open-Label, Phase 1 Study in Healthy Adult Subjects to Examine the Effects of Multiple-Dose Ciprofloxacin on Ivacaftor and VX-661 in Combination With IvacaftorCompletedNCT02015507Phase 1

← Tezacaftor overview